Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel
ConditionB-cell Mediated Autoimmune Disorders
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-62
SponsorTG Therapeutics, Inc.
About this trial
The main objective of this study is to collect data on the long-term safety of azer-cel, primarily through the capture of clinical events of interest (CEI) for up to 15 years following participation in TG-Azercel -101 study.
Eligibility criteria
Qualifiers
Received at least 1 dose of azer-cel in TG-Azercel -101 study.
Signed informed consent form (ICF).
Willingness and ability to adhere to the study schedule and all other protocol requirements.
Disqualifiers
None
Trial design
Treatments tested in this trial
- No Intervention
Treatment groups
32 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov